CRVS · Corvus Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| ORBIMED ADVISORS LLC Director | ▼ Sell | Open Market | 7,165,006 Shares held | 6/27/2025 | View profile |
| Richard A. Miller, MD President and CEO | ▲ Buy | Open Market | 1,195,035 Shares held | 5/18/2026 | View profile |
| Peter A. Thompson Director | ▲ Buy | Option Exercise | 210,000 Shares held | 1/28/2026 | View profile |
| William Benton Jones See Remarks | ▲ Buy | Option Exercise | 173,130 Shares held | 6/4/2025 | View profile |
| LEA LEIV Chief Financial Officer | ▲ Buy | Open Market | 133,238 Shares held | 12/14/2022 | View profile |
| EcoR1 Capital, LLC 10% Owner | ▼ Sell | Open Market | 81,077 Shares held | 10/1/2021 | View profile |
| David Scott Moore | ▲ Buy | Open Market | 21,700 Shares held | 6/11/2026 | View profile |
| Linda Grais Director | ▲ Buy | Open Market | 10,000 Shares held | 5/15/2023 | View profile |
Transaction History
| David Scott Moore | ▲ Buy | Open Market | 21,700 | $250K | 6/11/2026 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 5,000 | $60K | 5/18/2026 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 1,932 | $23K | 5/18/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 30,000 | $450K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $146K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $188K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $54K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $30K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $49K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $41K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $39K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $15K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $14K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $37K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $25K | 1/28/2026 |
| Peter A. Thompson | ▲ Buy | Option Exercise | 15,000 | $32K | 1/28/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 1,397,684 | $4.9M | 6/27/2025 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 1,176,332 | $4.9M | 6/27/2025 |
| Peter A. Thompson | ▼ Sell | Other | 1,397,684 | $4.9M | 6/27/2025 |
| Peter A. Thompson | ▼ Sell | Open Market | 1,176,332 | $4.9M | 6/27/2025 |
| William Benton Jones | ▲ Buy | Option Exercise | 19,357 | $68K | 6/4/2025 |
| Richard A. Miller, MD | ▲ Buy | Option Exercise | 559,073 | $2.0M | 5/7/2025 |
| Richard A. Miller, MD | ▼ Sell | Gift | 302,016 | $0 | 5/10/2024 |
| William Benton Jones | ▲ Buy | Open Market | 20,000 | $35K | 5/6/2024 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 577,634 | $1000K | 5/6/2024 |
| Linda Grais | ▲ Buy | Open Market | 10,000 | $25K | 5/15/2023 |
| William Benton Jones | ▲ Buy | Open Market | 20,000 | $16K | 12/20/2022 |
| LEA LEIV | ▲ Buy | Open Market | 4,000 | $3K | 12/14/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 10,000 | $8K | 12/14/2022 |
| LEA LEIV | ▲ Buy | Open Market | 30,000 | $22K | 12/13/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 50,000 | $37K | 12/13/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 25,000 | $19K | 9/28/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 12,300 | $10K | 9/20/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 2,700 | $2K | 9/20/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 5,000 | $4K | 9/20/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 5,000 | $5K | 6/27/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 5,000 | $5K | 6/24/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 890 | $899 | 6/6/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 4,830 | $5K | 6/2/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 170 | $165 | 6/2/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 15,000 | $25K | 3/31/2022 |
| LEA LEIV | ▲ Buy | Open Market | 13,878 | $23K | 3/17/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 5,000 | $8K | 3/17/2022 |
| LEA LEIV | ▲ Buy | Open Market | 35,160 | $54K | 3/16/2022 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 25,000 | $37K | 3/15/2022 |
| EcoR1 Capital, LLC | ▼ Sell | Open Market | 2,000,000 | $9.9M | 10/1/2021 |
| EcoR1 Capital, LLC | ▼ Sell | Open Market | 3,000,000 | $15.1M | 9/30/2021 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 1,109,644 | $6.8M | 9/20/2021 |
| Peter A. Thompson | ▼ Sell | Open Market | 1,109,644 | $6.8M | 9/20/2021 |
| Richard A. Miller, MD | ▲ Buy | Open Market | 10,000 | $19K | 8/20/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript Released
Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.
Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.